Swarna Sanzida S, Aziz Kashif, Zubair Tayyaba, Qadir Nida, Khan Mehreen
Internal Medicine, Sir Salimullah Medical College, Dhaka, BGD.
Internal Medicine, Icahn School of Medicine at Mount Sinai, New York, USA.
Cureus. 2019 Jul 28;11(7):e5256. doi: 10.7759/cureus.5256.
The prevalence of pruritus in chronic kidney disease (CKD) patients has varied over the years, and some studies suggest the prevalence may be coming down with more effective dialysis. Chronic kidney disease-associated pruritus (CKD-aP), previously called uremic pruritus, is a distressing symptom experienced by patients with mainly advanced chronic kidney disease. CKD-aP is associated with poor quality of life, depression, anxiety, sleep disturbance, and increased mortality. The incidence of CKD-aP is decreasing given improvements in dialysis treatments, but approximately 40% of patients with end-stage renal disease experience CKD-aP. While the pathogenesis of CKD-aP is not well understood, the interaction between non-myelinated C fibers and dermal mast cells plays an important role in precipitation and sensory stimulation. Other causes of CKD-aP include metabolic abnormalities such as abnormal serum calcium, parathyroid, and phosphate levels; an imbalance in opiate receptors is also an important factor. CKD-aP usually presents as large symmetric reddened areas of skin, often at night. Managing CKD-aP is a challenge. Research in this area is difficult because most studies are not comparable given their small group samples, study designs, and lack of standardized study measures. The most commonly used treatment is a combination of narrow-band ultraviolet B phototherapy and a μ-opioid receptor antagonist such as naltrexone.
慢性肾脏病(CKD)患者瘙痒症的患病率多年来有所变化,一些研究表明,随着透析效果的提高,患病率可能会下降。慢性肾脏病相关瘙痒症(CKD-aP),以前称为尿毒症瘙痒症,是主要患有晚期慢性肾脏病的患者所经历的一种痛苦症状。CKD-aP与生活质量差、抑郁、焦虑、睡眠障碍和死亡率增加有关。鉴于透析治疗的改善,CKD-aP的发病率正在下降,但约40%的终末期肾病患者会出现CKD-aP。虽然CKD-aP的发病机制尚不完全清楚,但无髓鞘C纤维与皮肤肥大细胞之间的相互作用在引发和感觉刺激中起重要作用。CKD-aP的其他原因包括代谢异常,如血清钙、甲状旁腺和磷酸盐水平异常;阿片受体失衡也是一个重要因素。CKD-aP通常表现为皮肤大片对称发红区域,常在夜间出现。管理CKD-aP是一项挑战。该领域的研究很困难,因为大多数研究由于样本量小、研究设计和缺乏标准化研究措施而缺乏可比性。最常用的治疗方法是窄带紫外线B光疗与μ-阿片受体拮抗剂(如纳曲酮)联合使用。